Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma
Status:
Completed
Trial end date:
2019-07-30
Target enrollment:
Participant gender:
Summary
A randomized, multicenter, double-blind, placebo- controlled parallel-group study to
determine the efficacy and safety of QAW039, compared with placebo, when added to
standard-of-care (SoC) asthma therapy in adult and adolescent (≥ 12 years) patients with
uncontrolled asthma with respect to change from baseline in forced expiratory volume in 1
second (FEV1) at the end of 12 weeks of treatment.